Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

This study investigated cetuximab added to definitive concurrent chemoradiation for esophageal squamous cell carcinoma (ESCC). Previously untreated patients with stage II–IVa ESCC received cetuximab (400 mg/m(2) per week in week 1, then 250 mg/m(2) per week during weeks 2–8), paclitaxel (45 mg/m(2)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Chen, Yongshun, Wu, Xiaoyuan, Bu, Shanshan, He, Chunyu, Wang, Wen, Liu, Jinsong, Guo, Wei, Tan, Bo, Wang, Yanxia, Wang, Jianhua
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2012
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5439109/
https://ncbi.nlm.nih.gov/pubmed/22845557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02393.x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki